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Abstract
Background: The composition and function of the adipose tissue covering the heart are poorly known. In this
study, we have investigated the epicardial adipose tissue (EAT) covering the cardiac ventricular muscle and the EAT
covering the left anterior descending artery (LAD) on the human heart, to identify their resident stem cell functional
activity.
Methods: EAT covering the cardiac ventricular muscle was isolated from the apex (avoiding areas irrigated by
major vessels) of the heart (ventricular myocardium adipose tissue (VMAT)) and from the area covering the
epicardial arterial sulcus of the LAD (PVAT) in human hearts excised during heart transplant surgery. Adipose stem
cells (ASCs) from both adipose tissue depots were immediately isolated and phenotypically characterized by flow
cytometry. The different behavior of these ASCs and their released secretome microvesicles (MVs) were investigated
by molecular and cellular analysis.
Results: ASCs from both VMAT (mASCs) and the PVAT (pASCs) were characterized by the expression of CD105,
CD44, CD29, CD90, and CD73. The angiogenic-related genes VEGFA, COL18A1, and TF, as well as the miRNA126-3p
and miRNA145-5p, were analyzed in both ASC types. Both ASCs were functionally able to form tube-like structures
in three-dimensional basement membrane substrates. Interestingly, pASCs showed a higher level of expression of
VEGFA and reduced level of COL18A1 than mASCs. Furthermore, MVs released by mASCs significantly induced
human microvascular endothelial cell migration.
Conclusion: Our study indicates for the first time that the resident ASCs in human epicardial adipose tissue display
a depot-specific angiogenic function. Additionally, we have demonstrated that resident stem cells are able to
regulate microvascular endothelial cell function by the release of MVs.
Keywords: Epicardial adipose tissue, Perivascular adipose tissue, Ventricular myocardium adipose tissue, Adipose
stem cells, Microvesicles, Angiogenesis
Background
Cardiovascular diseases (CVDs) are the leading cause of
death and disability worldwide, and coronary artery dis-
ease makes up the greatest proportion of those deaths.
Acute myocardial infarction leads to an irreversible loss
of proper cardiac function; implantation of adult stem
cells into the ischemic damaged myocardium has been
investigated for its potential to repair/regenerate the in-
jured tissue within the infarct zone [1–4].
Adipose tissue (AT) has long been considered an energy
storage and an endocrine organ. However, in the last de-
cades, adipose tissue has also been considered a rich
source of mesenchymal cells and is currently the focus of
interest in the field of inducible spontaneous regeneration
and cell therapy. Adipose-derived stem cells (ASCs) are
easily obtained, show a strong capacity for ex vivo expan-
sion and differentiation to other cell types (as cardiomyo-
cytes [5] or endothelial cells [6, 7]), release a large variety
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of angiogenic factors, and have immunomodulatory prop-
erties. All these properties have encouraged its use to in-
duce ischemic tissue recovery. However, their clinical use
of bone marrow stem cells has been hampered by the rec-
ognition of the loss of function effects of aging, cardiovas-
cular risk factors (CVRFs), and metabolic disorders [8].
Indeed, regarding spontaneous endogenous repair, our
group has shown that the presence of CVRFs, such as type
2 diabetes mellitus, negatively affects the pluripotency and
self-renewal capacities of adipose stem cells (ASCs) [9],
and ASCs obtained from obese patients display an im-
paired angiogenic potential [10, 11]. Indeed, the spontan-
eous regenerative capacity for ASC self-renewal seems to
be regulated by the anatomical WAT depot.
Besides the commonly known CVRFs that are known to
elevate the risk of suffering CVDs, excess adiposity is con-
sidered a CVRF for CVD [12]. The relationship between
obesity and the development of any CVDs lies not only in
the amount of fat, but also in its localization. AT is highly
heterogeneous tissue due to its different types (white,
brown, and “brite”) and its different body localizations
(subcutaneous, visceral, epicardial, and perivascular, etc.).
Composition, structure, and function of adipose tissue are
highly dependent on individual metabolic factors that we
are still learning. Ectopic AT covering different organs
may have different anatomic and functional characteristics
and due to its proximity to various internal organs may
exert organ-specific regulatory functions [13].
AT that directly surrounds the heart is known as epi-
cardial adipose tissue (EAT). EAT, a thoracic fat depot
that exists on the surface of the myocardium and is con-
tained entirely beneath the pericardium, has acquired in-
creasing interest because of its proximity to the
myocardium and coronary arteries and their branches
[12]. EAT has been reported to exert an endocrine role
by deregulation of adipokine secretion [14, 15] and to
have direct effects on local inflammation and coronary
atherosclerosis [16–18]. EAT is also a source of ASCs,
and it has been reported that these cells may have a
higher cardiomyogenic potential as compared to pericar-
dial and omental ASCs subtypes [19].
ASCs not only have interest for their capacity to differ-
entiate into differentiated cells, as cardiomyocytes, but also
for their capacity to stimulate angiogenesis promoting
progenitor cell differentiation and paracrine proangiogenic
and immunomodulatory effects [20]. The proangiogenic
effects of conditioned medium derived from ASCs support
this paracrine view of stem cell function [4]. Previous
studies indicated that microvesicles (MVs) released by
ASCs mediate their proangiogenic effects by cell-to-cell
communication stimulating formation and stabilization of
vessel formation [21]. However, little is known about epi-
cardial ASCs, in particular, those located closely to the
vessels [AT around vessels is known as perivascular AT
(PVAT)] and those residents in the EAT directly superim-
posed on the cardiac muscle (VMAT) covering the apex
of the heart. The contribution to these two stem cell reser-
voirs to cardiac cell function and to cardiac endogenous
repair processes after an ischemic injury is unknown. As
the coronary arteries and their major branches are imbed-
ded in PVAT, this creates a perfect environment for the
local interaction between ASCs present in this fat and the
coronary vessels it surrounds. Angiogenesis is essential for
the repair of wounded or ischemic organs, and insufficient
angiogenic switch in an ischemic heart can limit revascu-
larization, healing, and regeneration [22].
Here, we hypothesized that EAT from two different lo-
cations in the human heart may contain a repository of
stem cells (ASCs) with different pro-angiogenic functions.
Materials and methods
Sample collection/patients
VMAT and PVAT were obtained from the excised
hearts of 30 patients undergoing cardiac transplant sur-
gery at the Hospital de Sant Pau i la Santa Creu
(Table 1). Only samples from 3 patients were excluded,
2 of them due to internal cell contamination and the
other 1 due to endocarditis. Tissue was obtained with in-
formed consent of patients. The protocol was approved
by the Research Ethics Committee of our hospital and
was conducted in accordance with the Declaration of
Helsinki. Patients until the moment of transplant surgery
were treated as recommended by clinical practice guide-
lines. Left anterior descending (LAD) coronary arteries
were collected and PVAT isolation. Arteries were fixed
in 4% paraformaldehyde and stored at − 80 °C embedded
in OCT until histological analysis.
Table 1 Clinical characteristics of the study patients
Variables Patients
N 30
Age (years) 54 ± 3
Sex (M/W) 19/11
BMI (kg/m2) 27.4 ± 1.0
Obesity (%) 33.3
Overweigh (%) 20
Preserved FE (%) 20





Values are expressed as mean ± SD or as percentages, when indicated
CVRFs cardiovascular risk factors, HTA hypertension, DM diabetes mellitus,
DLP dyslipidemia
*Five years ex-smokers were considered non-smokers
**Treated as per guidelines
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Simultaneously, epicardial adipose tissue directly overly-
ing the ventricular myocardium at the apex of the heart
(VMAT) was collected. All studies were run in parallel
with samples from both locations from the same patients.
Both VMAT and PVAT were carefully dissected and fro-
zen in liquid N2 and kept at − 80 °C until used or placed
in tubes with 10mL of Dulbecco’s modified Eagle’s
medium (DMEM; Gibco, Life Technologies, Grand Island,
NY, USA) supplemented with 1% penicillin/streptomycin
(P/S, Gibco, Life Technologies, Grand Island, NY, USA) to
be immediately processed to isolate ASCs.
ASC isolation and characterization
PVAT and VMAT tissues were washed with sterile
phosphate-buffered saline (PBS) supplemented with 1% of
P/S. Tissue was digested into a type I collagenase solution
(1mg/mL; Sigma-Aldrich, St. Louis, MO, USA) and incu-
bated for 1 h in a 37 °C pre-warmed orbital shaker. Collage-
nase activity was neutralized with the same amount of fetal
bovine serum (FBS; Biological Industries, Kibbutz Beit-
Haemek, Israel) and the suspension filtered through a 100-
μm strainer to eliminate remaining tissue fragments. Then,
the suspension was centrifuged at 1200 rpm for 10min to
separate the adipocytes and to obtain the stromal vascular
fraction (SVF). Isolated SVF cells were counted and sepa-
rated into two aliquots to be analyzed by flow cytometry
and to be plated onto 25-cm2 culture flasks. After 24 h,
non-adherent cells were removed and the medium re-
placed. Cells were expanded in a humidified environment
at 37 °C with 1% O2 and 5% CO2 and maintained at sub-
confluent levels prior to phenotypic profile analysis. The
cells were characterized as stem cells by using the following
criteria: adherence to plastic, cell surface antigen phenotyp-
ing, and differentiation into multiple cell lineages. All ana-
lyses were performed between passages 3 and 4. A
simplified scheme of the procedure is shown in Fig. 1.
For cell cytometry characterization, cell surface antigen
phenotyping was performed on SVF and ASCs obtained
from SVF at passage 3 (P3). The following cell surface epi-
topes were marked with anti-human antibodies: CD105,
CD44, CD29, CD90, CD73, CD45, and CD14. Cells (1 ×
105) at passage 3 or 1mL of the SVF was suspended in
flow cytometry buffer (PBS, 0.1% BSA, 0.1% sodium azide)
and incubated for 30min at 4 °C with the corresponding
antibodies. After that, the reaction was stopped by adding
500 μL of flow cytometry buffer or 250 μL of Quicklysis
reagent (Cytognos) in the case of the SVF. Quicklysis was
incubated for 15min at room temperature to eliminate
erythrocytes, and the reaction was stopped by adding
250 μL of flow cytometry buffer.
Cellular events (at least 30,000 in the case of ASCs
and between 10,000 and 60,000 in the case of the SVF)
were acquired and analyzed by fluorescence-activated
cell sorting using Coulter EPICS XL flow cytometer
(Beckman Coulter) running Expo32 ADC XL 4 color
software (Beckman Coulter).
Adipogenic and osteogenic differentiation was also eval-
uated for further characterization as previously described
[11]. Briefly, cells were seeded in 6-well and 24-well plates
for the differentiation assay and for RNA isolation or cell
staining, respectively. Cells were allowed to grow to sub-
confluence (approximately 80% of confluence) and then
Fig. 1 Study design. Ventricular myocardium adipose tissue (VMAT) and perivascular adipose tissue (PVAT) were obtained during heart transplant
surgery. ASCs were immediately isolated and phenotypically characterized by flow cytometry
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allowed to differentiate for 21 days with the corresponding
conditional medium or normal medium without supple-
ments as a negative control (Additional file 1: Table S1).
After 21 days, RNA from the differentiated cells was iso-
lated, and also, cells were stained with Oil Red to detect
adipogenic differentiation and Alizarin red to detect osteo-
genic differentiation.
Growth kinetics of ASCs
To determine the growth kinetics of ASCs, 2 × 104 cells
per well were seeded in ten wells of 6-well plates. Cells
from two duplicate wells were harvested and counted
every other day for 10 days (cells were counted on days
2, 4, 6, and 10). ASC number was plotted against the
number of days cultured. Population doubling time
(PDT) was calculated using the formula PDT = Te/[(log
N2 − log N1)/log2], where Te is time (days) in the expo-
nential growth phase, N1 is the number of cells at the
beginning, and N2 is the number of cells at the end of
the experiment.
MTS viability/proliferation analysis
Cell proliferation was determined by 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfopheny)-2H-
tetrazolium (MTS) assay (CellTiter 96 Aqueous One Solu-
tion cell proliferation assay kit; Promega). For this assay,
15 × 103 of ASCs or 1 × 104 human microvascular endothe-
lial cells (HMEC-1) were seeded in triplicates into 96-well
plates. ASCs were cultured for 24 h and then treated with
10 μL of MTS. HMEC-1 were cultured for 24 h then treated
with ASC-derived MVs for other 24 h, and finally, 10 μL of
MTS per well was added and incubated for an additional 2
h, while MTS tetrazolium is reduced to formazan (490 nm
absorbance) by the metabolically active cells. The absorb-
ance was then quantified with the spectrophotometer Spec-
tramax 250 and analyzed with the SoftMax software
(Molecular Devices). Formazan production was directly re-
lated with the number of cells alive in the culture.
Tube-like formation assay
Tube-like formation assay in three-dimensional basement
membrane culture was employed to assess the angiogenic
potential of ASCs. Briefly, 1 × 105 cells were seeded in a
Matrigel-coated plate and incubated with endothelial cell
growth medium (EGM-2 BulletKit, Lonza, USA) for 24 h
to allow the formation of tube-like structures. The total
tube-covered area was quantified using ImageJ software
(National Institutes of Health, USA).
ASC-conditioned medium collection
Cells at passage 3 or 4 were allowed to grow until reach-
ing sub-confluence, then cells were washed exhaustively
with PBS to remove FBS and serum-free medium was
added. After 48 h, the ASC-conditioned medium was
collected and centrifuged at 1200 rpm for 10 min to re-
move cellular debris and kept at − 80 °C until used.
Microvesicle isolation
ASC-derived microvesicles (MVs) were isolated by ultra-
centrifugation of P3 cell supernatants as previously de-
scribed [23]. Briefly, fresh supernatants were firstly
centrifuged at 900g for 15min to eliminate cell debris and
then at 20,000g for 45min to isolate the MVs as a pellet.
MV concentration was determined by flow cytometry. For
that, MVs were washed with a PBS-citrate buffer and cen-
trifuged again at 20,000g for 30min. MVs were extracted
with PBS-citrate buffer and incubated with Annexin V
(CF Blue ANXV, Immunostep) and anti-TF antibody
(FITC-conjugated 4508CJ, Sekisui). Samples were then di-
luted with Annexin V binding buffer (BD Bioscience) to
stop the reaction and then analyzed on a FACSCantoll™
flow cytometer (BD Bioscience). The formation of MVs
after cell activation is initiated by the increase of intracel-
lular calcium resulting in an elementary rearrangement of
the phospholipid asymmetry with translocation of phos-
phatidylserine from the inner to the outer surface leaflet
of the plasma membrane as a consequence of activation of
scramblase and floppase/ABC1 and inhibition of translo-
case/flippase activities. The presence of phosphatidylserine
at the surface of the MP membrane enables the use of the
Annexin V for MVs detection by flow cytometry. MVs’
gate limits were established following two criteria: (1) cali-
bration using a Flow-Check Size Range Calibration Kit
(Polysciences) and (2) using an in vitro platelet-derived
microparticle population as a positive control. The lower
detection limit was placed as a threshold above the elec-
tronic noise of our flow cytometer.
Cell migration
HMEC-1 were used for the cell migration assays. Briefly,
2.3 × 104 eASCs were seeded into 100-mm dish and cul-
tured with MCDB 131 medium supplemented with 10%
of FBS for 48 h to allow cells to secrete MVs. The day
after, 2.5 × 105 HMEC-1 cells were seeded into a
Culture-Insert 2 well dish (Idibi) and kept with MCDB
131 supplemented with 10% of FBS overnight. MVs from
the eASC supernatant (eMVs) were isolated, and before
performing the experiment, the insert was removed by
using sterile tweezers and the dish washed with PBS to
remove cell debris. Cells were treated with 600 μL of (A)
conditional medium from ASCs after 48 h of culture, (B)
conditional medium from ASCs without eMVs after 48 h
of culture, and (C) eMV-enriched medium after 48 of
culture. In all conditions, medium was supplemented
with 2% of FBS. Cell migration and wound repair were
controlled every 2 h for 10 h. Wound areas were ana-
lyzed using ImageJ software. Protein, RNA, and micro-
RNA were isolated from the ASCs; microRNA from the
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eMVs and RNA; and microRNA from the HMEC-1 cells
after 24 h of cell migration.
Gene expression analysis
Total RNA was isolated from ASCs in silica membrane
columns with the Qiagen RNesasy Mini Kit (Qiagen) ac-
cording to the manufacturer’s instructions.
MirVana miRNA isolation kit (Life Technologies) was
used to extract microRNA from the cells, and miRNeasy
Serum/Plasma Kit for the microRNA isolation from
MVs, according to the manufacturer’s instruction.
RNA and microRNA quantity was determined with
Nanodrop ND-1000 spectrophotometer (Nanodrop Tech-
nologies). Isolated total RNA was reverse-transcribed into
cDNA using the High Capacity cDNA Archive kit (Ap-
plied Biosystems, Foster City, CA, USA) and microRNA
with the TaqMan advanced miRNA assay (Life Technolo-
gies). Gene expression analysis was carried out by quanti-
tative PCR using TaqMan® Gene Expression assays
(Applied Biosystems; Additional file 1: Table S2) and the
Applied Biosystems Prism 7900HT Sequence Detection
System (Applied Biosystems) according to manufacturer’s
instructions. Gene expression data are expressed as target
gene mRNA expression relative to the correspondent
housekeeping gene expression.
Western blot analysis
Protein was extracted from total cell lysates by using RIPA
buffer (50mM Tris-HCl pH 8, 150mM NaCl, 1% NP-40,
0.5% sodium deoxycholate, 0.1% SDS) or from 48 h cell
supernatant. Protein concentrations were measured with the
Pierce BCA Protein Assay Kit (ThermoScientific). Twenty-
five micrograms of protein was resolved by 1-DE under
reducing conditions onto 10% SDS-PAGE gels and electro-
transferred to nitrocellulose membranes. After blocking for
non-specific binding with 5% of bovine serum albumin
(BSA; MP Biomedical) or Blotto, the membranes were incu-
bated with primary antibodies, including TF (4501-Sekisui
Diagnostics), endostatin (ab109660-abcam), and VEGF
(ab51745-abcam). Band detection was performed using a
chemiluminiscent substrate dye (SuperSignal® West Dura Ex-
tended Duration Substrate, Thermo Scientific, Waltham,
MA, USA) and a molecular imager ChemiDoc XRS System,
Universal Hood II (BioRad, Hercules, CA, USA). Band quan-
tification was performed with Image Lab 4.0 software
(BioRad Laboratories, Hercules, CA, USA). Protein load was
normalized with total protein staining, and normalization be-
tween different membranes was performed with a common
pool in every gel, as previously described [24].
Statistical analysis
Non-parametric Wilcoxon or Mann-Whitney analyses
were performed to analyze the differences between tis-
sues. Data are expressed as mean ± SEM unless stated.
The level of significance was set at P < 0.05. All analyses
were conducted with StatView software.
Results
Sample characterization
Heart adipose tissue and LAD coronary arteries were
collected at the operating room during heart transplant-
ation surgery. LAD coronary arteries were classified ac-
cording to the AHA classification from intimal
thickening (IT) to type VI and total occlusion (TO)
(Additional file 1: Figure S2A-H). ASCs were isolated
immediately after tissue dissection, harvested, and char-
acterized by their adherence to plastic, their ability to
differentiate into multiple cell lineages, and the expres-
sion of different cell surface markers. ASCs were positive
to CD29, CD44, CD73, CD90, and CD105, and charac-
teristic mesenchymal stem cell surface markers, and
negative for the hematopoietic marker CD45 and the
monocyte marker CD14 (Fig. 2a). These results show
that the adipose tissue covering the human heart is a re-
pository for stem cells.
Proliferation and viability of ASCs from the different
adipose tissue depots
The proliferative rate of ASCs obtained from VMAT
(mASCs) was always higher than that of ASCs obtained
from PVAT (pASCs) (Fig. 2b); however, the main change
was observed during the first 4 days; thus, the calculated
doubling time of mASCs and pASCs was almost the same
during days 6 and 8 (Fig. 2c). Interestingly, the cellular via-
bility MTS assay demonstrated a significantly higher via-
bility in mASCs than in pASCs (P = 0.001; Fig. 2d) after
24 h in culture.
In vitro angiogenic-related gene expression of apex EAT-
and PVAT-derived ASCs
In order to evaluate the angiogenic potential of mASCs
and pASCs, different angiogenic-related genes were
measured. pASCs showed a significantly higher mRNA
expression of VEGFA compared with apex-derived ASCs
(N = 15; P = 0.04; Fig. 3a) and a significantly reduced
mRNA level of COL18a1 (N = 15; P = 0.02; Fig. 3b). In-
stead, pASCs and mASCs showed similar mRNA expres-
sion levels of TF (N = 12; P = 0.24; Fig. 3c), FGF2 (N = 6;
P = 0.46; Fig. 3d), and TIE2 (N = 7; P = 0.31; Fig. 3e).
Protein levels of TF and endostatin were also measured
by western blot, and a non-significant higher level of TF
on pASC compared to mASC (P = 0.093; Additional file 1:
Figure S2A) was observed. Endostatin levels were mea-
sured both in cells and secretome, but no differences were
observed between tissues (Additional file 1: Figure S2B-C).
The ability of both ASCs to form tube-like structures
was investigated. Both mASCs and pASCs had a similar
capacity to induce tube-like formation in Matrigel cultures
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(Additional file 1: Figure S3A and B, N = 9; P = 0.21). The
ability to form tubes by pASCs derived from LADs
with mild atherosclerosis (N = 4; IT to grade III) and
pASCs derived from LAD with severe atherosclerosis
(N = 5; grade IV occlusion to TO) was not signifi-
cantly different (Additional file 1: Figure S3C).
Effect of obesity and diabetes on eASCs released
microvesicle function
Because of the impact of obesity in adipose tissue accu-
mulation and fat characteristics, we investigated whether
mASC-derived microvesicles (mMVs) could exert a
regulatory effect on human microvascular endothelial
cell proliferation. First, we observed that mASCs from
obese non-diabetic patients release less mMVs than
those ASCs from obese diabetic patients (P = 0.06;
Fig. 4a). Interestingly, obese and diabetic mASC-released
mMVs have significantly higher levels of Annexin V
than those released by non-obese non-diabetic patients
(P = 0.03; Fig. 4a). Annexin V binds to phosphatidylser-
ine that is usually exposed in the outer leaflet of the
plasma membrane of cells that are activated or apoptotic
and released in the microvesicles. Next, we analyzed
whether these MVs were also positive for TF, because
previous studies in our group have described that TF-
rich microvesicles increase angiogenesis in ischemic tis-
sue [25]. The mMVs from mASCs of non-obese and
non-diabetic patients (total or Annexin V positive) con-
tain significantly higher TF amount than those mASCs
from obese non-diabetic patients (P = 0.004 and P = 0.02,
respectively; Fig. 4a). mMVs from mASCs of obese non-
diabetic patients also contain less TF than mMVs from
mASCs of obese diabetic patients (P = 0.02; Fig. 4a).
We then analyzed the microRNA (miRNA) compos-
ition of those eMVs. We analyzed two different miRNAs
that have been implicated in ASCs and the angiogenic
process as miRNA 126-3p and miRNA 145-5p [26, 27].
We found that mMVs from mASCs of non-obese non-
diabetic patients had a significantly higher content of
miRNA 126-3p than those mMVs from mASCs of obese
diabetic patients (P = 0.05; Fig. 4b). Non-significant
change was observed on miRNA 145-5p (Fig. 4c).
To evidence the effects of mASC-secreted mMVs on
human microvascular endothelial cell function, we first
Fig. 2 ASC characterization. a Flow cytometry analysis. Surface mesenchymal stem cell markers were analyzed from the stromal vascular fraction
(SVF) and from cells at passage 3. Data is presented as percentage of positive cells. b Growth curves of mASC and pASV. Cells were counted
every day after and plotted in a line curve graph. c Population doubling time (PDT) of mASC and pASC measured every 2 6 for 10 days. d MTS
viability assay (**P < 0.01)
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performed a MTS viability assay and no significant effects
on cell viability after treatment with mMVs was observed;
however, HMEC cells treated with mMVs from non-obese
non-diabetic patients showed a non-significant improve-
ment on HMEC viability (Additional file 1: Figure S4A).
The effect of mASC-secreted mMVs on HMEC-1 mi-
gration showed that, after 10 h of incubation, those
wounds treated with mMV-free secretome were signifi-
cantly less able to repair the wounded area compared with
those treated with mMV-rich medium (P = 0.05; Fig. 4d),
with the highest effect seen when HMEC-1 cells were
treated with mMVs released by mASC from obese dia-
betic patients (Additional file 1: Figure S4B-D).
To evidence the effect of mMVs on receptor HMEC-1
cells, we analyzed the mRNAs and the miRNAs expres-
sions in the receptor cells that had been incubated with
the supernatants of EAT-ASCs. We observed no change
on TF expression (Fig. 5a) nor in miRNA 126-3p (Fig. 5c)
and miRNA 145-5p (Fig. 5d), but a significant increase
on VEGFA (Fig. 5b) expression induced by both total
CM (P = 0.01) and mMV-free medium (P = 0.01), imply-
ing effects independent of MVs but associated with sol-
uble factors.
These results indicate that obesity and diabetes impact
on the pro-angiogenic capacity of resident stem cells
and explain the low spontaneous regenerative efficacy of
stem cells in patients with metabolic syndromes.
Discussion
The EAT has emerged as a depot with a distinctive bio-
logical significance in cardiac function. Moreover, it is a
reservoir of ASCs, with yet undefined effects on the po-
tential regeneration of ischemic tissue. Here, we show
that ASCs contained in different EAT locations obtained
from patients with advanced heart failure requiring
transplant have distinct functional properties.
The relationship of the adipose tissue with CVD has
been widely studied [28, 29]. Around 80% of the heart is
covered by visceral ectopic adipose tissue depots, which in
lean subjects is considered cardioprotective because of the
Fig. 3 Boxplot diagram showing ASC genomic profile. a Differential protein expression of VEGFA in mASC and pASC. b Differential protein
expression of COL18a1 in mASC and pASC. c Differential protein expression of TF in mASC and pASC. d Differential protein expression of FGF2 in
mASC and pASC. e Differential protein expression of TIE2 in mASC and pASC (*P < 0.05; **P < 0.01)
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Fig. 4 mASC microvesicle (mMV) secretion. a–c Influence of obesity and diabetes on eASC-derived MVs. a Number of mMVs measured by flow
cytometry (total, Annexin V-positive, TF-positive, and Annexin V/TF-positive mMVs). b miR126 relative gene expression. c miR145 relative gene
expression. d Healing rate line diagram of HMEC-1 cells treated with mASC total medium, mMV-depleted medium, or eMV-rich medium
(*P < 0.05; **P < 0.01)
Fig. 5 Effect of mASC-derived MVs on HMEC-1. Genomic changes of HMEC-1 cells produced by the treatment with mASC total medium, mMV-
depleted medium, or mMV-rich medium. a HMEC-1 VEGFA gene expression. b HMEC-1 TF gene expression. c HMEC-1 miR126 gene expression. d
HMEC-1 miR145 gene expression (*P < 0.05)
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secretion of anti-inflammatory and anti-atherogenic adi-
pokines. However, excess and thickness of fat around the
heart, usually measured by imaging techniques, have been
associated with CVD [16, 30]. Although imaging has
brought a growing interest in the presence of heart EAT,
it has not been possible to functionally study this adipose
tissue as widely as it has been done with other more ac-
cessible depots [31].
The ectopic visceral adipose tissue covering the heart
can be sub-classified by location and as perivascular fat
and fat directly overlying the myocardium, with blood
supplies directly derived from the coronary arteries and
their branches [32, 33]. The function of the stem cells
found in these adipose tissue depots has not been stud-
ied in-depth. This study has focused on the identifica-
tion, isolation, and comparison, for the first time, of the
ASCs covering the LAD (PVAT) and the ASCs covering
the ventricular myocardium at the apex (VMAT) of
hearts explanted during heart transplant operations.
These ASCs were characterized by their adherence to
plastic as well as by the expression of different stem cell
markers (CD90, CD105, CD44, CD29, and CD73) and
the absence of the leukocyte marker CD45 and the in-
nate immune system marker CD14. Thus, both fat loca-
tions have a significant amount of resident stem cells.
We have observed that mASCs have a higher prolifera-
tive rate and growth kinetics than pASC, which might
suggest that mASCs are cells with an active participation
in local regenerative activity and homeostasis. Due to
the angiogenic activity of adipose tissue [34], we investi-
gated the genomic angiogenic profile of these cells. Even
though there are many proteins involved in the angio-
genic process, VEGF is undoubtedly the most important
angiogenic factor. It is a potent mitogen for endothelial
cells (ECs), involved both in the development of the vas-
cular system and the induction and maintenance of the
neovasculature in tumors. VEGF binds to any of the
tyrosine kinase receptors (VEGFR1 or VEGFR2), which
induce the phosphorylation of the tyrosine residues, thus
activating intracellular signaling pathways involved in
EC proliferation, migration, and survival [35, 36]. On the
other hand, COL18A1 is a gene that encodes the anti-
angiogenic protein endostatin in its C-terminal domain
[37]. Endostatin inhibits EC proliferation and migration
and induces EC apoptosis by blocking the binding of
VEGF with the tyrosine receptor KDR (VEGFR-2) [38].
We found that pASCs express a higher amount of
VEGFA, as well as a reduced expression of COL18A1,
compared with the mASCs, suggesting a coordinated
regulation of angiogenesis through these two proteins by
EAT-derived ASCs, which is increased on pASC, in dir-
ect contact with the LAD compared with mASC. By
contrast, no differences by location were achieved in
other genes as TF, TIE2, and FGF-2. The role of these
genes in angiogenesis is well established [39–41]; in fact,
FGF-2 induces the formation of new capillary-like tu-
bules on HMEC cells [42]. However, in line with our re-
sults, in previous studies, no differences were observed
when comparing the expression of FGF-2 in ASC from
different sources, but changes on these proteins were
obtained as a result of the age of the donor [43]. TIE-2
is related with the ANGPT system [44]; thus, a deep
study on this pathway is needed for the better under-
standing of this new source of epicardial ASC.
Few studies have analyzed the presence and function
of heart adipose tissue-derived stem cells, neither in ani-
mal [45, 46] nor in human [19] models, and in none of
them, their angiogenic potential has been analyzed and
compared. Previous studies in our group have shown
how ASCs derived from the subcutaneous adipose tissue,
independently of the BMI, have no ability to form tubes
in a Matrigel-based experiment [11], but here, we dem-
onstrate for the first time that both mASCs and pASCs,
when seeded in a 3D Matrigel surface and cultured with
EGM-2 medium, are able to form capillary-like ring
structures, independently of cardiac fat location and of
atherosclerosis severity in the LAD indicating a proan-
giogenic function. More studies are needed to analyze
the influence of different co-morbidities on heart adi-
pose tissue and its derived ASC.
Angiogenesis is mediated not only by VEGFA [47] and
COL18A1 [48], but also by many other genes, such as
fibroblast growth factor (FGF), angiopoietin I and II
(ANGPT I-II) [41], and NOTCH [49] among others, and
target cells include endothelial cells (EC) and vascular
smooth muscle cells (VSMCs) [50, 51] were involved.
In fact, a coordinated reaction between different cellu-
lar types and metabolic factors is needed for the correct
development of the angiogenic process [52]. It would
also be of great interest to analyze the adipokines se-
creted by these EATs and resident ASCs to further
characterize both epicardial heart depots and their po-
tential implication on myocardial self-regeneration.
Spontaneous regeneration of damaged tissue may be ac-
complished not only by ASC differentiation and also by
ASC-released microvesicles (MVs) and exosomes [53, 54].
MVs are small particles with a diameter ranging from 0.10
to 1.00 μm released by many cell types, including ASCs
[55]. The potential of MVs released by ASCs to improve
HUVEC migration, proliferation, and angiogenesis has
been reported [56, 57]. Many studies support the concept
of a proangiogenic effect of MVs depends on their com-
position, conferring to them a dynamic storage pool of
bioactive molecules that play essential roles in cell-cell
crosstalk. In this way, MVs can provide intercellular com-
munication by the delivery of miRNAs to influence tran-
scription and altering genetic processes. miRNA126-3p is
one of the more important miRNAs in angiogenesis [58],
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and it has been described to be present in MVs. In line
with these results, we have also demonstrated that heart
mASCs from non-obese and non-diabetic heart failure pa-
tients release mMVs, rich in miRNA126-3p, that improve
microvascular endothelial cells (HMEC-1) viability and
are more effective than mASC-conditioned medium
(CM), or mMV-depleted medium in inducing angiogen-
esis. mMVs also increase HMEC-1 migration rate, inde-
pendently on the presence of CVRFs, and HMEC-1
wounds in vitro are closed faster when treated with mMVs
from obese diabetic patients. In this regard, it has been re-
ported that MVs released from subcutaneous ASCs of
obese subjects have impaired pro-angiogenic potential and
harbor reduced VEGF, MMP-2, and miR-126 content
than those released by ASCs of non-obese subjects, redu-
cing their capability to promote EC migration and tube-
like structure formation [26]. In addition, previously, we
have found that TF-rich MVs increase neovascularization
in ischemic tissue [23], and here, we observed that mASCs
have high levels of TF that may induce the angiogenic
properties of these MVs and are decreased in obese and
diabetic patients. HMEC-1 treated with eASC supernatant
(CM, MV-free medium or MV-rich medium) increases
the expression of VEGFA, suggesting a potential way of
action of ASC extracellular particles (not only MVs, but
also exosomes and other secreted factors). TF induces
angiogenesis by ETS1 transcription factor [59], and VEGF
is a target gene of ETS1 [60]. However, more experiments
on this field should be carried out to elucidate the precise
mechanism of action of each different extracellular par-
ticle depending on ASC origin.
Limitations
As a limitation, we have to report the low number of
cases in this study, but the number of heart transplants
in one single hospital is low. Organ donations are dis-
tributed among patient waiting lists in many different
hospitals. The methods and technologies reported here
have to be performed immediately with hearts directly
obtained by research investigators waiting at the surgical
room to receive the excised heart. At the annex of the
operating room, the hearts are sampled and taken from
the operating room within minutes in the appropriated
buffers to the cell biology laboratory for further process-
ing. Therefore, only in-hospital transplants could be
used. Many other genes and pathways would be analyzed
if more hearts were available.
Conclusions
In the present study, we demonstrate for the first time that
hearts from patients with advanced heart failure requiring
transplant have ASCs in their different heart adipose tissue
depots and that these ASCs have distinct functional proper-
ties. Additionally, we have demonstrated the potential role
of mASC-derived microvesicles on endothelial cell migra-
tion that could represent a promising strategy to stimulate
spontaneous regeneration and repair in rarefaction areas of
the damaged myocardium. Tissue activation and
mobilization of resident ASCs could be a potential means
to reduce the progression of disease in failing hearts.
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